EN DE
Watch Dabomb Protein for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Dabomb Protein (6578) fair value: what the stock is really worth

As of Oct 28, 2026: fair value (intrinsic value) of Dabomb Protein stock TWD 1.79, price TWD 17.30, upside -89.7%, quality 32 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive TW · ISIN TW0006578008

DP Dabomb Protein logo Thin data Oct 29, 2026

Dabomb Protein

6578 · TWO
Very expensive, weak qualityPrice far above fair value, weak quality and a downtrend.Plus: Last quarter vs. a year ago: revenue +18%, profit +164%.

Our calculation puts a fair price 90% below what the stock costs today.

Low debt
Fair value 1.79 TWD · Strongly overvalued (−89.7%)
Quality 32/100
Weak Growth (revenue 5y −12.6 %/yr in TWD)
Loss-making · -12.4% net margin (TTM)
Negative free cash flow
Trails peers (4/12)
Narrow moat 16/100 · thin data
Thin data
Watch Dabomb Protein for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

31.46 TWD 12.01 TWD Fair Value 1.79 TWD May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.

How to read this chart

60‑month range 12.01 TWD – 31.46 TWD · fair‑value band 1.21 TWD – 2.37 TWD · the 17.30 TWD price screens above the 1.79 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Oct 29, 2026.

Follow Dabomb Protein in your weekly email

Every Wednesday you see whether Dabomb Protein is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

DaBomb Protein Biotech Corp. manufactures and sells hydrolyzed soy protein in Vietnam, the Philippines, South Korea, Taiwan, and Asia. It offers nutrition and health care for aquatic products and economic animals; and pet health care products.

Show moreShow less

The company also offers contract development and manufacturing organization services, including research and development, process design, and mass production services; product packaging solutions; and product formulation design and customized development services.

It serves pet health food brands, pet nutrition product distribution channels, livestock feed enterprises, animal nutrition brands, and aquaculture industries. The company was formerly known as DaBomb Protein Corp. and changed its name to DaBomb Protein Biotech Corp. in October 2023.

DaBomb Protein Biotech Corp. was incorporated in 2001 and is based in Tainan City, Taiwan.

Stock analysis

Dabomb Protein (6578) currently trades at 17.30 TWD, while our model-based Fair Value estimate is 1.79 TWD, 89.7% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 1.21 TWD (bear) to 2.37 TWD (bull), the price of 17.30 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Consumer Defensive sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Dabomb Protein reported revenue of 309M TWD in FY2025 versus 471M TWD in FY2021, a compound −10.0%/yr. Reported net income was −69.3M TWD in FY2025.

Key figures

Market cap 1.2B TWD (≈ $38.2M) Micro · P/S ratio 3.63 · EPS (TTM) −0.5800 TWD · Net margin −12.4% · Return on equity −4.1% · Return on assets (EBIT) −2.9% · Operating margin 9.4% · Revenue (TTM) 339M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −18% fair-value upside, at −90%, 6578 screens richer than that median.

Fair Value models

Bear 1.21 TWD Fair Value 1.79 TWD Bull 2.37 TWD
Price 17.30 TWD · Upside -89.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA 1.21 TWD 1.79 TWD 2.37 TWD 66
NCAV (Graham) 1.09 TWD 1.66 TWD 2.07 TWD 54
All 2 models by family
Multiples
EV/EBITDA 1.21 TWD 1.79 TWD 2.37 TWD 66
Asset-Based
NCAV (Graham) 1.09 TWD 1.66 TWD 2.07 TWD 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 27
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 84
Debt, balance sheet and risk of trouble
Investment 63
Does it invest with discipline instead of growing at any price?
Low Volatility 85
How calm the share price moves, does not count
Momentum 40
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 29
Distance to the 52-week high, does not count
New shares 11
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−8.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.6%
Start year 2020 (pandemic). Over 10 years: −9.1% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.3% (2020) → −9.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6578 screens overvalued: fair value 90% below the price. Compare with Nestlé S.A →

Compare Dabomb Protein with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 629 stocks

Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −89.7% · Bottom 25%
Profitability
Return on assets −6.3% · Bottom 25%
Net margin (12 months) −12.4% · Bottom 25%
Operating margin (12 months) 9.4% · Above median
Growth and dividend
Revenue growth (quarter YoY) 18.3% · Top 25%
Dividend yield (12 months) 0.0% · Bottom 25%
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Packaged Foods median · lower = cheaper

P/B 1.26× · Cheaper than median
P/S (12 months) 3.67× · Priciest 25%
EV/EBITDA 48.2× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 37
FUTURE (revenue growth)92 · sector 23
PAST (return on equity)0 · sector 31
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 57

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wilmar International Limited F34 3.27 SGD 5.89 SGD +80% vs 6578
Inner Mongolia Yili Industrial Group 600887 ¥28.89 ¥41.84 +45% vs 6578
The Kraft Heinz Company KHC $24.06 $29.20 +21% vs 6578
Foshan Haitian Flavouring and Food Company 603288 ¥34.48 ¥37.93 +10% vs 6578
Danone S.A BN €61.62 €50.65 −18% vs 6578
Nestlé S.A NESN CHF 83.73 CHF 59.51 −29% vs 6578
Kerry Group KRZ €96.95 €60.33 −38% vs 6578
Nestlé India Limited NESTLEIND ₹1,181 ₹724.74 −39% vs 6578
General Mills, Inc GIS $33.47 $19.61 −41% vs 6578
Yihai Kerry Arawana Holdings 300999 ¥25.90 ¥12.21 −53% vs 6578

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dabomb Protein · Fair Value
1.79 TWD −90%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Dabomb Protein Fair Value". https://www.fairvalue-calculator.com/stock/6578

Frequently asked questions

Is Dabomb Protein (6578) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of 1.79 TWD versus a price of 17.30 TWD, about −90% upside (overvalued).
What is the fair value of 6578?
Our model-based fair value for Dabomb Protein is 1.79 TWD (as of Oct 29, 2026), built from audited fundamentals. The current price: 17.30 TWD.
What is the quality score of 6578?
Dabomb Protein has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dabomb Protein (6578)?
Our model-based price target is the fair value of 1.79 TWD (as of Oct 29, 2026) from 2 valuation models. Cautious scenario 1.21 TWD, optimistic scenario 2.37 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Dabomb Protein stock forecast for 2026?
Our models put fair value at 1.79 TWD, about −90% upside versus a price of 17.30 TWD (overvalued). Cautious scenario 1.21 TWD, optimistic scenario 2.37 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Dabomb Protein (6578)?
Dabomb Protein reported trailing-twelve-month revenue of about 339M TWD (latest available figure, as of Oct 29, 2026).
What is the intrinsic value of Dabomb Protein (6578)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dabomb Protein it is 1.79 TWD per share (as of Oct 29, 2026), against a price of 17.30 TWD. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Dabomb Protein stock overvalued or undervalued in 2026?
As of Oct 29, 2026, 6578 trades above its calculated fair value: price 17.30 TWD, fair value 1.79 TWD, a gap of about −90% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6578?
No. The price is what the market pays today (17.30 TWD); the fair value is what the company's own numbers justify (1.79 TWD). For Dabomb Protein the two are 15.51 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Dabomb Protein worth?
The market values Dabomb Protein at about 1.2B TWD (market capitalisation, as of Oct 29, 2026). Per share that is 17.30 TWD; our models calculate a fair value of 1.79 TWD per share.
What do the bullish and bearish scenarios say about 6578?
Our models span a range for Dabomb Protein: cautious scenario 1.21 TWD, base 1.79 TWD, optimistic 2.37 TWD per share (as of Oct 29, 2026, price 17.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Dabomb Protein (6578)?
Balance-sheet figures for Dabomb Protein (as of Oct 29, 2026): return on equity −4.1%, debt of 0.02 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is 6578 from its 52-week high?
Dabomb Protein trades at 17.30 TWD, about 17% below its 52-week high of 20.75 TWD and 18% above the low of 14.65 TWD (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 1.79 TWD is for.
Which stocks are comparable to Dabomb Protein?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dabomb Protein stock attractive at the current price?
The data as of Oct 29, 2026: price 17.30 TWD, calculated fair value 1.79 TWD (−90%), Quality Score 32/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6578 calculated?
We run Dabomb Protein through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.79 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Dabomb Protein itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dabomb Protein (6578)?
The closing price on Oct 28, 2026 was 17.30 TWD. Our model-based fair value is 1.79 TWD, about −90% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dabomb Protein right now?
The price sits above even our optimistic bull case (2.37 TWD). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1.21 TWD to 2.37 TWD) leaves room in how you read the outcome.

Key figures of Dabomb Protein

How large is the market capitalisation of Dabomb Protein (6578)?
The market capitalisation of Dabomb Protein is 1.2B TWD (≈ $38.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dabomb Protein (6578)?
The price-to-sales ratio of Dabomb Protein is 3.63 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dabomb Protein (6578)?
Earnings per share at Dabomb Protein are −0.5800 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Dabomb Protein (6578)?
The net margin of Dabomb Protein is −12.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dabomb Protein (6578)?
The return on equity (ROE) of Dabomb Protein is −4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dabomb Protein (6578)?
On an EBIT basis the return on assets of Dabomb Protein is −2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dabomb Protein (6578)?
The operating margin of Dabomb Protein is 9.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dabomb Protein (6578)?
Revenue at Dabomb Protein is growing +18.3% versus a year earlier (3y avg −10.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Dabomb Protein (6578)?
Earnings per share at Dabomb Protein are growing +164% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Dabomb Protein (6578) generate?
The free cash flow of Dabomb Protein is −21.0M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Dabomb Protein (6578) carry?
The net debt of Dabomb Protein is 38.0M TWD (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Dabomb Protein in the live analysis

One click puts Dabomb Protein on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.